全文获取类型
收费全文 | 35544篇 |
免费 | 3474篇 |
国内免费 | 2490篇 |
专业分类
耳鼻咽喉 | 286篇 |
儿科学 | 463篇 |
妇产科学 | 414篇 |
基础医学 | 4132篇 |
口腔科学 | 650篇 |
临床医学 | 4615篇 |
内科学 | 5436篇 |
皮肤病学 | 377篇 |
神经病学 | 1836篇 |
特种医学 | 1438篇 |
外国民族医学 | 14篇 |
外科学 | 3971篇 |
综合类 | 5807篇 |
现状与发展 | 7篇 |
一般理论 | 4篇 |
预防医学 | 2367篇 |
眼科学 | 807篇 |
药学 | 3836篇 |
31篇 | |
中国医学 | 2013篇 |
肿瘤学 | 3004篇 |
出版年
2024年 | 101篇 |
2023年 | 487篇 |
2022年 | 1177篇 |
2021年 | 1724篇 |
2020年 | 1296篇 |
2019年 | 1181篇 |
2018年 | 1208篇 |
2017年 | 1170篇 |
2016年 | 1163篇 |
2015年 | 1615篇 |
2014年 | 1957篇 |
2013年 | 1838篇 |
2012年 | 2385篇 |
2011年 | 2750篇 |
2010年 | 1813篇 |
2009年 | 1401篇 |
2008年 | 1840篇 |
2007年 | 1903篇 |
2006年 | 1810篇 |
2005年 | 1749篇 |
2004年 | 1400篇 |
2003年 | 1439篇 |
2002年 | 1238篇 |
2001年 | 1062篇 |
2000年 | 906篇 |
1999年 | 850篇 |
1998年 | 493篇 |
1997年 | 573篇 |
1996年 | 384篇 |
1995年 | 337篇 |
1994年 | 276篇 |
1993年 | 217篇 |
1992年 | 254篇 |
1991年 | 234篇 |
1990年 | 211篇 |
1989年 | 184篇 |
1988年 | 150篇 |
1987年 | 151篇 |
1986年 | 129篇 |
1985年 | 85篇 |
1984年 | 57篇 |
1983年 | 35篇 |
1982年 | 18篇 |
1981年 | 21篇 |
1980年 | 26篇 |
1979年 | 46篇 |
1978年 | 22篇 |
1976年 | 12篇 |
1975年 | 19篇 |
1974年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Zeyu Li Erwei Hao Rui Cao Si Lin Linghui Zou Tianyan Huang Zhengcai Du Xiaotao Hou Jiagang Deng 《中草药(英文版)》2022,14(4):479-493
Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group". 相似文献
2.
3.
Xiumei Jiang Xiaowei Zhang Patrick Gray Jiwen Zheng Timothy R. Croley Peter P. Fu 《journal of environmental science and health part c-environmental carcinogenesis & ecotoxicology reviews》2019,37(2):116-131
Gold nanoparticles (Au NPs) hold great promise in food, industrial and biomedical applications due to their unique physicochemical properties. However, influences of the gastrointestinal tract (GIT), a likely route for Au NPs administration, on the physicochemical properties of Au NPs has been rarely evaluated. Here, we investigated the influence of GIT fluids on the physicochemical properties of Au NPs (5, 50, and 100?nm) and their implications on intestinal epithelial permeability in vitro. Au NPs aggregated in fasted gastric fluids and generated hydroxyl radicals in the presence of H2O2. Cell studies showed that GIT fluids incubation of Au NPs affected the cellular uptake of Au NPs but did not induce cytotoxicity or disturb the intestinal epithelial permeability. 相似文献
4.
当代社会,老年人口比例呈现不断上升的趋势,老龄化问题日益严峻。因此,如何有效地延缓衰老不仅成为了世界医学研究的热点,也成为了全球亟待解决的问题。中医药在延缓衰老方面经验丰富,而滋阴药在此类研究中效果显著。本文通过整理滋阴药抗衰老作用机制的若干文献,对滋阴复方六味地黄丸、二至丸、左归丸及其他滋阴中药延缓衰老的机制研究进展进行综述。 相似文献
5.
6.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
7.
8.
9.
10.